| Actemra IV (tocilizumab) / Roche, JW Pharma |
NCT01396317: Study of Tocilizumab to Treat Polymyalgia Rheumatica |
|
|
| Completed | 2a | 10 | US | Tocilizumab, Actemra | Hospital for Special Surgery, New York, Genentech, Inc. | Polymyalgia Rheumatica (PMR) | 12/15 | 01/16 | | |
NCT00144651: Study of MRA in Patients With Rheumatoid Arthritis (RA) |
|
|
| Completed | 2 | 135 | Japan | MRA(Tocilizumab) | Chugai Pharmaceutical | Rheumatoid Arthritis | 06/09 | 06/09 | | |
| Completed | 2 | 76 | Europe | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 12/10 | 12/10 | | |
NCT01242488 / 2010-020839-39: Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy |
|
|
| Completed | 2 | 221 | US, Europe | CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv | UCB Pharma | Rheumatoid Arthritis | 06/12 | 06/12 | | |
|
|
|
NCT00845832 / 2008-005525-11: A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate |
|
|
| Terminated | 2 | 24 | Europe | Placebo, rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 03/13 | 03/13 | | |
NCT01468077 / 2011-002363-15: A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment |
|
|
| Completed | 2 | 47 | Europe, RoW | Tocilizumab, RoActemra, Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 09/13 | 09/13 | | |
| Completed | 2 | 21 | Europe | TCZ | University Hospital, Brest, Chugai Pharmaceutical | Polymyalgia Rheumatica | 10/14 | 10/14 | | |
|
|
NCT01450137: Tocilizumab for Patients With Giant Cell Arteritis |
|
|
| Completed | 2 | 30 | Europe | Tocilizumab + Glucocorticoids (GCs), Placebo + Glucocorticoids (GCs) | University Hospital Inselspital, Berne, University of Bern, Roche Pharma AG | Giant Cell Arteritis | 12/14 | 09/15 | | |
HORTOCI, NCT01910038: Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. |
|
|
| Completed | 2 | 20 | Europe | corticoids+ tocilizumab 8mg/Kg/4 weeks | Centre Hospitalier Universitaire Dijon | Giant Cell Arteritis | 12/15 | 06/16 | | |
NCT01603355: Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis |
|
|
| Terminated | 1/2 | 3 | US | Tocilizumab, Actemra | Eric B. Suhler, Genentech, Inc. | Juvenile Idiopathic Arthritis Associated Uveitis | 02/16 | 02/16 | | |
NCT03062579: A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD |
|
|
| Completed | 1/2 | 10 | RoW | Tocilizumab, ACTEMRA® | Fu-Dong Shi | Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica, Devic's Disease | 02/18 | 05/18 | | |
